Loading data for ENVB — first visit, this takes a few seconds.
Enveric Biosciences, Inc. (ENVB): цена акции, анализ и данные
Внутренняя стоимость
Прогноз аналитиков
Прогнозы по акции →Последние результаты
| Отчитано | К прогнозу | Изменение г/г | |
|---|---|---|---|
| Выручка | $0 | n/a | n/a |
| EPS | -$2,03 | +$0,73 | +98.94% |
Метрики
- Бид
- 1.08
- Рыночная капитализация
- 6.62M
- Выручка (TTM)
- n/a
- Чистая прибыль (TTM)
- -12.1M
- 1.11
- -12.18
- n/a
- -1.05
- P/B (TTM)
- 0.72
- P/S (TTM)
- n/a
- Дата отчёта
- n/a
- Аск
- 1.81
- Объём торгов
- 104,183
- Ср. объём (20д)
- 120,341
- Открытие
- 1.48
- Пред. закрытие
- 1.44
- Диапазон дня
- 1.41 - 1.54
- Диапазон за 52 недели
- 1.17 - 13.25
- Аналитики
- n/a
- Целевая цена
- n/a
- Дивиденды
- n/a
- Дата отсечки
- Apr 23, 2008
О компании Enveric Biosciences, Inc.
Профиль →Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.